<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUDROCORTISONE ACETATE - fludrocortisone acetate tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Fludrocortisone Acetate Tablets USP, 0.1 mg contain fludrocortisone acetate, a 
synthetic adrenocortical steroid possessing very potent mineralocorticoid 
properties and high glucocorticoid activity; it is used only for its 
mineralocorticoid effects. The chemical name for fludrocortisone acetate is 
9-fluoro-11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione 21-acetate; its 
structural formula is:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf927cd9-1891-4de4-b4be-743a26363a64&amp;name=chemical%20structure.jpg"></p>
<p>Fludrocortisone acetate tablets USP, 0.1 mg are available for oral 
administration as scored tablets providing 0.1 mg fludrocortisone acetate per 
tablet. Inactive ingredients: croscarmellose sodium NF, lactose monohydrate NF, 
magnesium stearate NF, and microcrystalline cellulose NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Corticosteroids are thought to act at least in part, by 
controlling the rate of synthesis of proteins. Although there are a number of 
instances in which the synthesis of specific proteins is known to be induced by 
corticosteroids, the links between the initial actions of the hormones and the 
final metabolic effects have not been completely elucidated. </p>
<p>The physiologic action of fludrocortisone acetate is similar to that of 
hydrocortisone. However, the effects of fludrocortisone acetate, particularly on 
electrolyte balance, but also on carbohydrate metabolism, are considerably 
heightened and prolonged. Mineralocorticoids act on the distal tubules of the 
kidney to enhance the reabsorption of sodium ions from the tubular fluid into 
the plasma; they increase the urinary excretion of both potassium and hydrogen 
ions. The consequence of these three primary effects together with similar 
actions on cation transport in other tissues appear to account for the entire 
spectrum of physiological activities that are characteristic of 
mineralocorticoids. In small oral doses, fludrocortisone acetate produces marked 
<span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> and increased urinary potassium excretion. It also causes a 
<span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, apparently because of these effects on electrolyte 
levels.</p>
<p>In larger doses, fludrocortisone acetate inhibits endogenous adrenal cortical 
secretion, thymic activity, and pituitary corticotropin excretion; promotes the 
deposition of liver glycogen; and, unless protein intake is adequate, induces 
negative nitrogen balance.</p>
<p>The approximate plasma half-life of fludrocortisone (fluorohydrocortisone) is 
3.5 hours or more and the biological half-life is 18 to 36 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Fludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement 
therapy for primary and <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> in Addison's 
disease and for the treatment of salt-losing adrenogenital syndrome.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Corticosteroids are contraindicated in patients with systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> 
and in those with a history of possible or known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to these 
agents.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">BECAUSE OF ITS MARKED EFFECT ON <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">SODIUM RETENTION</span> 
THE USE OF FLUDROCORTISONE ACETATE IN THE TREATMENT OF CONDITIONS OTHER THAN 
THOSE INDICATED HEREIN IS NOT ADVISED.</span></p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may 
appear during their use. There may be decreased resistance and inability to 
localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs during 
fludrocortisone acetate therapy, it should be promptly controlled by suitable 
antimicorbial therapy.</p>
<p>Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, 
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the 
establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses.</p>
<p>Average and large doses of hydrocortisone or cortisone can cause elevation of 
blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. 
These effects are less likely to occur with the synthetic derivatives except 
when used in large doses. However, since fludrocortisone acetate is a potent 
mineralocorticoid, both the dosage and salt intake should be carefully monitored 
in order to avoid the development of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. <span class="Bold">Periodic checking of serum electrolyte levels is advisable during 
prolonged therapy; dietary salt restriction and potassium supplementation may be 
necessary.</span> All corticosteroids increase calcium excretion.</p>
<p>Patients should not be vaccinated against <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span> while on corticosteroid 
therapy. Other immunization procedures should not be undertaken in patients who 
are on corticosteroids, especially on high dose, because of possible hazards of 
neurological complications and a lack of antibody response.</p>
<p>The use of fludrocortisone acetate in patients with active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> 
should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> 
in which the corticosteroid is used for the management of the disease in 
conjunction with an appropriate antituberculous regimen. If corticosteroids are 
indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close 
observation is necessary since reactivation of the disease may occur. During 
prolonged corticosteroid therapy these patients should receive 
chemoprophylaxis.</p>
<p>Children who are on immunosuppressant drugs are more susceptible to 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy children. Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have 
a more serious or even fatal course in children on immunosuppressant 
corticosteroids. In such children, or in adults who have not had these diseases, 
particular care should be taken to avoid exposure. If exposed, therapy with 
variicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin 
(IVIG), as appropriate, may be indicated. If chicken pox develops, treatment 
with antiviral agents may be considered.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<p class="First">Adverse reactions to corticosteroids may be produced by too rapid 
withdrawal or by continued use of large doses.</p>
<p>To avoid drug-induced <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, supportive dosage may be 
required in times of stress (such as <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or severe illness) both 
during treatment with fludrocortisone acetate and for a year afterwards.</p>
<p>There is an enhanced corticosteroid effect in patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> 
and in those with cirrhosis.</p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes 
simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>.</p>
<p>The lowest possible dose of corticosteroid should be used to control the 
condition being treated. A gradual reduction in dosage should be made when 
possible.</p>
<p>Psychic derangements may appear when corticosteroids are used. These may 
range from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or 
<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may also be aggravated by corticosteroids.</p>
<p>Aspirin should be used cautiously in conjunction with corticosteroids in 
patients with <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.</p>
<p>Corticosteroids should be used with caution in patients with nonspecific 
<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, 
or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Corticosteroids should also be used cautiously in 
patients with <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, active or latent 
<span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span> 
gravis.</p>
<a href="http://"></a><a href="http://"></a>Information for Patients<p>The physician should advise the patient to report any medical 
history of heart disease, high blood pressure, or kidney or liver disease and to 
report current use of any medicines to determine if these medicines might 
interact adversely with fludrocortisone acetate (see <span class="Bold"><a href="#section-8.4">Drug Interactions</a></span>).</p>
<p>Patients who are on immunosuppressant doses of corticosteroids should be 
warned to avoid exposure to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> and, if exposed, to obtain 
medical advice.</p>
<p>The patient's understanding of his steroid-dependent status and increased 
dosage requirement under widely variable conditions of stress is vital. Advise 
the patient to carry medical identification indicating his <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on steroid 
medication and, if necessary, instruct him to carry an adequate supply of 
medication for use in emergencies.</p>
<p>Stress to the patient the importance of regular follow-up visits to check his 
progress and the need to promptly notify the physician of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, severe or 
continuing <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">swelling of feet</span> or lower legs, or unusual weight 
gain.</p>
<p>Advise the patient to use the medicine only as directed, to take a missed 
dose as soon a possible unless it is almost time for the next dose, and not to 
double the next dose.</p>
<p>Inform the patient to keep this medication and all drugs out of the reach of 
children.</p>
<a href="http://"></a><a href="http://"></a>Laboratory Tests<p>Patients should be monitored regularly for blood pressure 
determinations and serum electrolyte determinations (see <span class="Bold"><a href="#section-7">WARNINGS</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>When administered concurrently, the following drugs may interact 
with adrenal corticosteroids.</p>
<p><span class="Italics">Amphortericin B</span> or <span class="Italics">potassium-depleting diuretics</span> (benzothiadiazines and 
related drugs, ethacrynic acid and furosemide)—enhanced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Check serum 
potassium levels at frequent intervals; use potassium supplements if necessary 
(see <span class="Bold"><a href="#section-7">WARNINGS</a></span>).</p>
<p><span class="Italics">Digitalis glycosides</span>— enhanced possibility of 
<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> associated with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Monitor serum 
potassium levels; use potassium supplements if necessary.</p>
<p><span class="Italics">Oral anticoagulants</span>— decreased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time 
response. Monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> levels and adjust anticoagulant dosage 
accordingly.</p>
<p><span class="Italics">Antidiabetic drugs</span> (oral agents and 
insulin)—diminished antidiabetic effect. Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; 
adjust dosage of antidiabetic drug upward if necessary.</p>
<p><span class="Italics">Aspirin</span>— increased ulcerogenic effect; decreased 
pharmacologic effect of aspirin. Rarely salicylate toxicity may occur in 
patients who discontinue steroids after concurrent high-dose aspirin therapy. 
Monitor salicylate levels or the therapeutic effect for which aspirin is given; 
adjust salicylate dosage accordingly if effect is altered (see <span class="Bold"><a href="#section-8.1">PRECAUTIONS, General</a></span>).</p>
<p><span class="Italics">Barbiturates, phenytoin,</span> or <span class="Italics">rifampin</span>— increased metabolic clearance of fludrocortisone 
acetate because of the induction of hepatic enzymes. Observe the patient for 
possible diminished effect of steroid and increase the steroid dosage 
accordingly.</p>
<p><span class="Italics">Anabolic steroids</span> (particularly C-17 alkylated 
<span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> such as oxymetholone, methandrostenolone, norethandrolone, and similar 
compounds)— enhanced tendency toward <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Use caution when giving these drugs 
together, especially in patients with hepatic or cardiac disease.</p>
<p><span class="Italics">Vaccines</span>— neurological complications and lack of 
antibody response (see <span class="Bold"><a href="#section-7">WARNINGS</a></span>).</p>
<p><span class="Italics">Estrogen</span>— increased levels of 
corticosteroid-binding globulin thereby increasing the bound (inactive) 
fraction; this effect is at least balanced by decreased metabolism of 
corticosteroids. When estrogen therapy is initiated, a reduction in 
corticosteroid dosage may be required, and increased amounts may be required 
when estrogen is terminated.</p>
<a href="http://"></a><a href="http://"></a>Drug/Laboratory Test Interactions<p>Corticosteroids may affect the nitrobluetetrazolium test for 
<span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> and produce false-negative results.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Adequate studies have not been performed in animals to determine 
whether fludrocortisone acetate has carcinogenic or mutagenic activity or 
whether it affects fertility in males or females.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><a href="http://"></a>Pregnancy: Teratogenic Effects: Category C<p>Adequate animal reproduction studies have not been conducted with 
fludrocortisone acetate. However, many corticosteroids have been shown to be 
teratogenic in laboratory animals at low doses. <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> of these agents 
in man has not been demonstrated. It is not known whether fludrocortisone 
acetate can cause fetal harm when administered to a pregnant woman or can affect 
reproduction capacity. Fludrocortisone acetate should be given to a pregnant 
woman only if clearly needed.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy: Nonteratogenic Effects<p>Infants born of mothers who have received substantial doses of 
fludrocortisone acetate during pregnancy should be carefully observed for signs 
of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
<p>Maternal treatment with corticosteroids should be carefully documented in the 
infant's medical records to assist in follow up.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Corticosteroids are found in the breast milk of lactating women 
receiving systemic therapy with these agents. Caution should be exercised when 
fludrocortisone acetate is administered to a nursing woman.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>Safety and effectiveness in children have not been 
established.</p>
<p>Growth and development of infants and children on prolonged corticosteroid 
therapy should be carefully observed.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Most adverse reactions are caused by the drug's mineralocorticoid 
activity (retention of sodium and water) and include <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, 
cardiac enlargement, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, potassium loss, and hypokalemic 
<span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>.</p>
<p>When fludrocortisone is used in the small dosages recommended, the 
glucocorticoid side effects often seen with cortisone and its derivatives are 
not usually a problem; however the following untoward effects should be kept in 
mind, particularly when fludrocortisone is used over a prolonged period of time 
or in conjunction with cortisone or a similar glucocorticoid.</p>
<p><span class="Italics">Musculoskeletal</span>—<span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, 
loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>, aseptic 
<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of femoral and humeral heads, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, and 
<span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">spontaneous fractures</span>.</p>
<p><span class="Italics">Gastrointestinal</span>—<span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible 
perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, and ulcerative 
<span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p><span class="Italics">Dermatologic</span>—impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, thin fragile 
skin, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, 
subcutaneous <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">fat atrophy</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, hyperpigmentation of the skin and 
nails, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; reactions to skin tests may be 
suppressed.</p>
<p><span class="Italics">Neurological</span>— <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, increased intracranial 
pressure with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (psuedotumor cerebri) usually after treatment, 
<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and severe mental disturbances.</p>
<p><span class="Italics">Endocrine</span>—menstrual irregularities; development of 
the <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state; suppression of growth in children; secondary 
adrenocortical and pituitary unresponsiveness, particularly in times of stress 
(e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness); decreased carbohydrate tolerance; 
manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus; and increased requirements for 
insulin or oral hypoglycemic agents in diabetics.</p>
<p><span class="Italics">Ophthalmic</span>— <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, 
<span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span>.</p>
<p><span class="Italics">Metabolic</span>— <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, and negative 
nitrogen balance due to protein catabolism.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span>— allergic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, 
<span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Other adverse reactions that may occur following the administration of a 
corticosteroid are necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, aggravation or 
masking of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, syncopal episodes, and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Development of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, excessive increase in weight, 
and increase in heart size are signs of overdosage of fludrocortisone acetate. 
When these are noted, administration of drugs should be discontinued, after 
which the symptoms will usually subside within several days; subsequent 
treatment with fludrocortisone acetate should be with a reduced dose. Muscular 
<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> may develop due to excessive potassium loss and can be treated by 
administering a potassium supplement. Regular monitoring of blood pressure and 
serum electrolytes can help to prevent overdosage (see <span class="Bold"><a href="#section-7">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage depends on the severity of the disease and the response of 
the patient. Patients should be continually monitored for signs that indicate 
dosage adjustment is necessary, such as remission or exacerbations of the 
disease and stress (surgery, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>)(see <span class="Bold"><a href="#section-7">WARNINGS</a></span> and <span class="Bold"><a href="#section-8.1">PRECAUTIONS, General</a></span>).</p>
<a href="http://"></a><a href="http://"></a>Addison's Disease<p>In Addison's disease, the combination of fludrocortisone acetate 
tablets with a glucocorticoid such as hydrocortisone or cortisone provides 
substitution therapy approximating normal adrenal activity with minimal risks of 
unwanted effects.</p>
<p>The usual dose is 0.1 mg of fludrocortisone acetate tablets daily, although 
dosage ranging from 0.1 mg three times a week to 0.2 mg daily has been employed. 
In the event transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> develops as a consequence of therapy, the 
dose should be reduced to 0.05 mg daily. Fludrocortisone acetate tablets are 
preferably administered in conjunction with cortisone (10 mg to 37.5 mg daily in 
divided doses) or hydrocortisone (10 mg to 30 mg daily in divided doses).</p>
<a href="http://"></a><a href="http://"></a>Salt-Losing Adrenogenital Syndrome<p>The recommended dosage for treating the salt-losing adrenogenital 
syndrome is 0.1 mg to 0.2 mg of fludrocortisone acetate tablets daily.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Italics">Fludrocortisone Acetate Tablets USP,</span> 
0.1 mg—Each white to off-white, round, convex tablet debossed with a "7033" on 
one side and with a bisect on the other side.</p>
<a name="i50905fb1-3f2e-4579-8715-fc9a0d80fc90"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 10<br>
</td>
<td>NDC 54868-5446-3<br>
</td>
</tr>
<tr>
<td>Bottles of 15<br>
</td>
<td>NDC 54868-5446-0<br>
</td>
</tr>
<tr>
<td>Bottles of 20<br>
</td>
<td>NDC 54868-5446-2<br>
</td>
</tr>
<tr>
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5446-4<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 60<br>
</td>
<td>NDC 54868-5446-1<br>
</td>
</tr>
</tbody></table>
<p></p>
<p>Store at controlled room temperature 15° to 30°C (59° to 86°F)(see USP). 
Avoid excessive heat.</p>
<p>Dispense in a tightly-closed, light-resistant container (USP).</p>
<a href="http://"></a><a href="http://"></a><p>Mfg. by:<br>IMPAX Laboratories, Inc.<br>30831 Huntwood 
Avenue<br>Hayward, California 94544</p>
<p>Dist. by:<br>Global Pharmaceuticals<br>Division of IMPAX Laboratories, 
Inc.<br>Philadelphia, PA 19124</p>
<p>218-01<br>rev. 7/01</p>
<br><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Italics">Fludrocortisone Acetate Tablets USP,</span><br></p>
<p>0.1 mg</p>
<p><img alt="image of 0.1 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf927cd9-1891-4de4-b4be-743a26363a64&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUDROCORTISONE ACETATE 		
					</strong><br><span class="contentTableReg">fludrocortisone acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5446(NDC:0115-7033-01)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUDROCORTISONE ACETATE</strong> (FLUDROCORTISONE) </td>
<td class="formItem">FLUDROCORTISONE ACETATE</td>
<td class="formItem">0.1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (White to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7033</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5446-0</td>
<td class="formItem">15  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5446-1</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5446-2</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-5446-3</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-5446-4</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040431</td>
<td class="formItem">10/06/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fd513374-c466-41fa-bd54-7017a52cd95a</div>
<div>Set id: bf927cd9-1891-4de4-b4be-743a26363a64</div>
<div>Version: 1</div>
<div>Effective Time: 20100903</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
